Glenmark Pharmaceuticals expects to achieve revenue between ₹17,000-18,000 crore by the financial year 2027, with a strong focus on branded medicines, respiratory products, and oncology therapies. The company anticipates broad-based growth across its key markets, including India, the US, Europe, and various emerging economies.
Strategic Growth Pillars
The drugmaker has set an ambitious target of 21-22% EBITDA margins for FY27. According to Anurag Mantri, Executive Director and Global Chief Financial Officer of Glenmark Pharmaceuticals, the company's established infrastructure across all markets positions it for significant expansion. "With infrastructure now in place across all markets, we expect broad-based growth," Mantri stated.
Glenmark is strategically shifting its portfolio, aiming for branded products to account for 70% of its total revenue by 2030, a substantial increase from the current 60%. This shift will be supported by new product launches, licensing agreements, and an expanded presence in therapeutic areas such as respiratory, dermatology, and oncology.
Global Market Expansion and Key Products
Growth is anticipated from a diverse geographic base. In emerging markets, which include the Middle East, Africa, Latin America, Asia-Pacific, Russia, and CIS countries, Glenmark plans launches of Aumolertinib this year, followed by Trastuzumab Rezetecan. A key success story is Ryaltris, now marketed in over 50 countries, which saw more than 50% growth in secondary sales during FY26 and is expected to generate over $200 million in annual sales over time.
The company has also strengthened its oncology portfolio through strategic licensing agreements. These include a significant deal with AbbVie for the investigational asset ISB 2001, valued at up to $1.925 billion in potential payments, and commercial rights for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma for India and emerging markets.
US and European Market Focus
In the United States, Glenmark's performance will be bolstered by respiratory medicines and injectables. The company secured approvals for generic Flovent HFA 44 mcg and Fluticasone Propionate Nasal Spray OTC in FY26, both of which were commercialized. Furthermore, the Monroe facility received a US FDA Establishment Inspection Report, allowing for resumed commercial manufacturing and supporting the expansion of its injectable business.
Europe will see contributions from Winlevi, following its launch in the UK and subsequent EU approval in FY26, establishing Glenmark's branded dermatology presence in the region.
Robust Performance in India
India remains a critical market for Glenmark. The domestic business grew 1.5 times faster than the overall Indian Pharmaceutical Market in FY26, making it the second-fastest-growing among the top 15 pharmaceutical companies, according to IQVIA data. Recent launches in India include Tevimbra and Brukinsa in oncology, Nebzmart GFB Smartules and Glenmark Airz FB Smartules for respiratory care, and Glipiq for diabetes.
Strong Financial Health
Glenmark concluded FY26 with a strong financial position, reporting consolidated revenue of ₹16,982.5 crore, a 27.5% year-on-year increase. EBITDA stood at ₹4,572.4 crore with a margin of 26.9%, and profit after tax was ₹1,362 crore. The company maintained a debt-free status and improved working capital efficiency, providing a solid foundation for future investments and sustained growth across its diverse businesses.